Hot topics in perioperative immune combination therapy for liver cancer
10.3760/cma.j.cn113884-20221204-00449
- VernacularTitle:肝癌围手术期免疫联合治疗热点问题
- Author:
Shichun LU
1
;
Biao GAO
;
Yafei WANG
Author Information
1. 解放军总医院肝胆胰外科医学部 解放军总医院肝胆外科研究所 全军数字肝胆外科重点实验室，北京 100853
- Keywords:
Carcinoma, hepatocellular;
Neoadjuvant therapy;
Immune combination therapy;
Conversion therapy;
Systemic therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2023;29(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Most patients with primary hepatocellular carcinoma (HCC) are already in advanced stage when they are diagnosed, with a short survival period and an extremely poor prognosis. HCC seriously threatens the life and health of Chinese people. In recent years, breakthroughs have been made in systemic treatment of HCC, especially in immunotherapy represented by immune checkpoint inhibitors, which has broken the single therapy situation of molecular targeted drugs. And the strategy of immunotherapy combined with anti-angiogenic therapy has shown superiority and profoundly changed the treatment strategy of HCC. This article focuses on several hotspots of immune checkpoint inhibitors combined with anti-angiogenic targeted drugs in the perioperative scenario of HCC, and takes stock of the latest research progress of immunotherapy combined with anti-angiogenic drugs regimens in the perioperative application of HCC.
